NovelDrop^TMMicrofluidic Single-Cell Capture Platform

Leveraging its self-developed pneumatic control system and patented microfluidic technology, NovelBio has launched its first automated single-cell sequencing system. The platform integrates proprietary microfluidic chips and flexible gel beads to achieve precise control over fluid flow and droplet generation. With an intelligent instrument interface, it streamlines the isolation and capture of target cells, significantly accelerating single-cell research workflows.

Technical Principle

NovelDrop^TM The NovelDrop™ Microfluidic Single-Cell Capture Platform operates on a dynamic microfluidics mechanism for isolating and capturing individual cells. Specifically, cell suspension, barcoded beads, and fluorinated oil flow through dedicated microchannels. Within the reaction system, the barcoded beads specifically bind to cells, which then pass through a fluorinated oil channel to achieve isolation, ultimately forming stable water-in-oil emulsion droplets for downstream analysis.

Practical Evaluation

Data-Driven Performance: A Look at the NovelDrop™ Platform's Results To evaluate performance, intestinal, lung, blood, and brain tissues from the same mouse were processed in parallel using the NovelDrop™ platform alongside established international microfluidic systems with both their latest and previous reagent versions.

Following library preparation and sequencing, a comparative analysis of clustering results from both platforms was performed using brain tissue as an example.

In the figure, yellow represents the legacy reagent from the international platform, green denotes the new reagent from the same platform, while blue corresponds to the clustering results from the NovelDrop™ microfluidic single-cell capture platform.

The results demonstrate highly consistent clustering patterns between the NovelDrop™ platform and the international microfluidic system. Subsequent cell type identification confirms minimal compositional differences across platforms.

Cell type identification in brain tissue revealed that the NovelDrop™ platform detected a higher proportion of glial cells compared to the international platform, with astrocytes particularly elevated—reaching 22.08%. The doublet rate of NovelDrop™ was comparable to the international platform's new reagent, while total cell capture increased by 40%. Notably, NovelDrop™ demonstrated a significantly lower doublet rate relative to the international platform's legacy reagent.

The NovelDrop™ Microfluidic Single-Cell Capture Solution combines proprietary instrumentation and reagents into a rigorously validated system. It demonstrates not only high consistency with leading international platforms but also superior performance in key metrics, delivering an exceptional cost-effective microfluidic solution for single-cell research.

Click to view detailed experimental results for intestinal, lung, and blood samples